| Similar Articles |
|---|
 |
The Motley Fool
June 13, 2008
Brian Orelli |
China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year.   |
The Motley Fool
July 9, 2008
Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. |
The Motley Fool
August 29, 2007
Billy Fisher |
China Medical Continues to Impress China Medical Technologies, the Chinese medical device maker, produces another quarter of incredible growth, which the company attributes to momentum from its in-vitro diagnostic business. |
BusinessWeek
September 5, 2005
Michael Arndt |
Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease. |
The Motley Fool
October 16, 2007
Brian Lawler |
Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note. |
The Motley Fool
July 15, 2008
Brian Lawler |
Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings? |
The Motley Fool
May 8, 2009
Brian Orelli |
Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector? |
Wired
July 2006
Kevin Kelleher |
Personalize It While Adidas offers customized shoes for your feet, the pharmaceutical industry is moving toward personalizing drugs based on your genes. |
The Motley Fool
February 13, 2006
W.D. Crotty |
China Medical Technologies Soars Cayman Islands-based China Medical Technologies reports strong third-quarter results. However, there are warnings signs for investors to consider. |
The Motley Fool
November 17, 2006
Brian Lawler |
Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
The Motley Fool
November 18, 2010
Brian Orelli |
Genzyme: Slimmed Down, Gussied Up But will anyone buy it? |
The Motley Fool
June 20, 2008
Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
Pharmaceutical Executive
September 1, 2010 |
The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development. |
The Motley Fool
June 13, 2008
Brian Lawler |
Glaxo Gears Up a Blockbuster One of the pharmaceutical's top new compounds scores final EU approval. |
The Motley Fool
March 29, 2007
Brian Lawler |
Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note. |
The Motley Fool
January 12, 2007
Brian Lawler |
Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector. |
The Motley Fool
April 8, 2004
Brian Gorman |
Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs. |
The Motley Fool
July 12, 2005
Charly Travers |
Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game? |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
The Motley Fool
April 13, 2007
Brian Lawler |
Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note. |
The Motley Fool
July 12, 2006
Stephen D. Simpson |
Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered. |
The Motley Fool
September 9, 2011
Frank Vinluan |
GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche. |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
PC Magazine
January 18, 2006
Carol A. Mangis |
Fish Tycoon A surprisingly absorbing game, Fish Tycoon puts you in charge of a tank with some starter fish. |
The Motley Fool
July 12, 2007
Brian Lawler |
Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried. |
The Motley Fool
January 26, 2010
Dave Mock |
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars. |
